{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:47Z","timestamp":1779148847105,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03359-5","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:39:47Z","timestamp":1757918387000},"page":"5365-5379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Narrative Review of the Immunomodulatory Effects of Acthar\u00ae Gel Beyond Its Steroidogenic Properties"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-8442","authenticated-orcid":false,"given":"Mehdi","family":"Mirsaeidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Affeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Berkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"7","key":"3359_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628\u201339.","journal-title":"N Engl J Med"},{"key":"3359_CR2","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.eclinm.2023.102193","volume":"64","author":"GBD 2019 IMID Collaborators","year":"2023","unstructured":"GBD 2019 IMID Collaborators. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the Global Burden of Disease study 2019. EClinicalMedicine. 2023;64:102193.","journal-title":"EClinicalMedicine"},{"key":"3359_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.110899","volume":"88","author":"AS Russell","year":"2011","unstructured":"Russell AS, Gulliver WP, Irvine EJ, Albani S, Dutz JP. Quality of life in patients with immune-mediated inflammatory diseases. J Rheumatol Suppl. 2011;88:7\u201319.","journal-title":"J Rheumatol Suppl"},{"key":"3359_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3899\/jrheum.110901","volume":"88","author":"P Jacobs","year":"2011","unstructured":"Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases\u2013focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55\u201361.","journal-title":"J Rheumatol Suppl"},{"issue":"18","key":"3359_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026411","volume":"11","author":"H Wassif","year":"2022","unstructured":"Wassif H, Saad M, Desai R, et al. Outcomes following acute coronary syndrome in patients with and without rheumatic immune-mediated inflammatory diseases. J Am Heart Assoc. 2022;11(18):e026411.","journal-title":"J Am Heart Assoc"},{"issue":"26","key":"3359_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007308","volume":"96","author":"B Fernandez-Gutierrez","year":"2017","unstructured":"Fernandez-Gutierrez B, Perrotti PP, Gisbert JP, et al. Cardiovascular disease in immune-mediated inflammatory diseases: a cross-sectional analysis of 6 cohorts. Medicine (Baltimore). 2017;96(26):e7308.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3359_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2\u201313.","journal-title":"Mol Cell Endocrinol"},{"key":"3359_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","volume":"10","author":"C Strehl","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744.","journal-title":"Front Immunol"},{"issue":"1","key":"3359_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1476-5381.2010.01199.x","volume":"163","author":"PJ Barnes","year":"2011","unstructured":"Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163(1):29\u201343.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3359_CR10","first-page":"89","volume":"101","author":"EL Dvorin","year":"2020","unstructured":"Dvorin EL, Ebell MH. Short-term systemic corticosteroids: appropriate use in primary care. Am Fam Physician. 2020;101(2):89\u201394.","journal-title":"Am Fam Physician"},{"issue":"4","key":"3359_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"3359_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1210\/endrev\/bnae008","volume":"45","author":"J Lockett","year":"2024","unstructured":"Lockett J, Inder WJ, Clifton VL. The glucocorticoid receptor: isoforms, functions, and contribution to glucocorticoid sensitivity. Endocr Rev. 2024;45(4):593\u2013624.","journal-title":"Endocr Rev"},{"issue":"9678","key":"3359_CR13","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","volume":"373","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905\u201317.","journal-title":"Lancet"},{"issue":"4","key":"3359_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cpdd.1020","volume":"11","author":"N Poola","year":"2022","unstructured":"Poola N, Due B, Wright D, Brooks LR, Zaman F. Pharmacokinetics and pharmacodynamics of repository corticotropin injection compared with synthetic ACTH1-24 depot and methylprednisolone in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(4):502\u201315.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3359_CR15","volume-title":"Full prescribing information","author":"Acthar\u00ae Gel (repository corticotropin injection)","year":"2024","unstructured":"Acthar\u00ae Gel (repository corticotropin injection). Full prescribing information. Bridgewater, NJ: Mallinckrodt Pharmaceuticals; 2024."},{"issue":"2","key":"3359_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-020-00199-3","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7(2):327\u201344.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"3359_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000383","volume":"7","author":"AD Askanase","year":"2020","unstructured":"Askanase AD, Zhao E, Zhu J, Connolly-Strong E, Furie RA. Acthar gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. Lupus Sci Med. 2020;7(1):e000383.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"3359_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cns.13789","volume":"28","author":"D Wynn","year":"2022","unstructured":"Wynn D, Goldstick L, Bauer W, et al. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. CNS Neurosci Ther. 2022;28(3):364\u201371.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"3359_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s41030-023-00222-2","volume":"9","author":"M Mirsaeidi","year":"2023","unstructured":"Mirsaeidi M, Baughman RP, Sahoo D, Tarau E. Results from a phase 4, multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for the treatment of pulmonary sarcoidosis. Pulm Ther. 2023;9(2):237\u201353.","journal-title":"Pulm Ther"},{"issue":"5","key":"3359_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3359_CR21","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40123-021-00400-y","volume":"10","author":"D Wirta","year":"2021","unstructured":"Wirta D, McLaurin E, Ousler G, Liu J, Kacmaz RO, Grieco J. Repository corticotropin injection (Acthar gel) for refractory severe noninfectious keratitis: efficacy and safety from a phase 4, multicenter, open-label study. Ophthalmol Ther. 2021;10(4):1077\u201392.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"3359_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.18502\/jovr.v16i2.9086","volume":"16","author":"SD Anesi","year":"2021","unstructured":"Anesi SD, Chang PY, Maleki A, et al. Treatment of noninfectious retinal vasculitis using subcutaneous repository corticotropin injection. J Ophthalmic Vis Res. 2021;16(2):219\u201333.","journal-title":"J Ophthalmic Vis Res"},{"key":"3359_CR23","unstructured":"Claris Biotherapeutics. Study to evaluate the safety and efficacy of CSB-001 ophthalmic solution 0.1% in subjects with limbal stem cell deficiency. https:\/\/clinicaltrials.gov\/study\/NCT06452316. Accessed 6 September 2024."},{"key":"3359_CR24","unstructured":"Affeldt JC. Novel use of Acthar gel and (purported) oremepermin for pharmacologic control and reversal of total limbal stem cell deficiency. Presented at: Sonoma Eye Conference; March 16\u201319, 2023; San Diego, CA."},{"issue":"8","key":"3359_CR25","first-page":"5154","volume":"64","author":"S Cho","year":"2023","unstructured":"Cho S, Ahmed H, Affeldt JC. Novel use of Acthar gel for treatment of inflammation driven progressive stage II limbal stem cell deficiency. Invest Ophthalmol Vis Sci. 2023;64(8):5154.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3359_CR26","unstructured":"Affeldt JC. Novel use of HP Acthar gel in the treatment of peripheral ulcerative keratitis. Presented at: Sonoma Eye; December 12-January 30, 2021; Virtual meeting."},{"key":"3359_CR27","volume-title":"Full Prescribing Information","author":"Purified Cortrophin\u00ae gel (repository corticotropin injection)","year":"2023","unstructured":"Purified Cortrophin\u00ae gel (repository corticotropin injection). Full Prescribing Information. Baudette, MN: ANI Pharmaceuticals Inc; 2023."},{"issue":"1","key":"3359_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/ijem.ijem_461_21","volume":"26","author":"S Atluri","year":"2022","unstructured":"Atluri S, Sarathi V, Goel A, et al. Long-acting porcine sequence ACTH (Acton Prolongatum) stimulation test is a reliable alternative test as compared to the gold standard insulin tolerance test for the diagnosis of adrenal insufficiency. Indian J Endocrinol Metab. 2022;26(1):38\u201343.","journal-title":"Indian J Endocrinol Metab"},{"key":"3359_CR29","unstructured":"Cosyntropin injection, for intravenous use. Full Prescribing Information. Princeton, NJ: Sandoz Inc.; 2018."},{"key":"3359_CR30","unstructured":"Synacthen\u00ae Depot ampoules 1 mg\/mL (tetracosactide acetate). Summary of Product Characteristics. Atnahs Pharma UK Ltd.; 2020."},{"issue":"1","key":"3359_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36469\/jheor.2021.18727","volume":"8","author":"MS Duchowny","year":"2021","unstructured":"Duchowny MS, Chopra I, Niewoehner J, Wan GJ, Devine B. A systematic literature review and indirect treatment comparison of efficacy of repository corticotropin injection versus synthetic adrenocorticotropic hormone for infantile spasms. J Health Econ Outcomes Res. 2021;8(1):1\u20139.","journal-title":"J Health Econ Outcomes Res"},{"issue":"5","key":"3359_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/10799893.2020.1818094","volume":"41","author":"YJ Huang","year":"2021","unstructured":"Huang YJ, Galen K, Zweifel B, Brooks LR, Wright AD. Distinct binding and signaling activity of Acthar gel compared to other melanocortin receptor agonists. J Recept Signal Transduct Res. 2021;41(5):425\u201333.","journal-title":"J Recept Signal Transduct Res"},{"issue":"2","key":"3359_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13066","volume":"223","author":"M Joels","year":"2018","unstructured":"Joels M, Karst H, Sarabdjitsingh RA. The stressed brain of humans and rodents. Acta Physiol (Oxf). 2018;223(2):e13066.","journal-title":"Acta Physiol (Oxf)"},{"issue":"7","key":"3359_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cpdd.894","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, Pham L, Poola N, Brooks LR, Due B. Comparison of steroidogenic exposure following the administration of repository corticotropin injection with a synthetic ACTH1-24 depot and methylprednisolone in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(7):777\u201388.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3359_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/CEOR.S410082","volume":"15","author":"GJ Wan","year":"2023","unstructured":"Wan GJ, Niewoehner J, Hayes K. Acthar gel (RCI): a narrative literature review of clinical and economic evidence. Clinicoecon Outcomes Res. 2023;15:499\u2013512.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"3359_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ckj\/sfw045","volume":"9","author":"W Kittanamongkolchai","year":"2016","unstructured":"Kittanamongkolchai W, Cheungpasitporn W, Zand L. Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis. Clin Kidney J. 2016;9(3):387\u201396.","journal-title":"Clin Kidney J"},{"issue":"1","key":"3359_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"7","key":"3359_CR38","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70321","volume":"13","author":"K Hayes","year":"2025","unstructured":"Hayes K, Wright D. Microarray analysis of the effects of Acthar Gel versus methylprednisolone in a model of focal segmental glomerulosclerosis in female rats. Physiol Rep. 2025;13(7):e70321.","journal-title":"Physiol Rep"},{"key":"3359_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fmed.2019.00145","volume":"6","author":"AE Moscowitz","year":"2019","unstructured":"Moscowitz AE, Asif H, Lindenmaier LB, Calzadilla A, Zhang C, Mirsaeidi M. The importance of melanocortin receptors and their agonists in pulmonary disease. Front Med (Lausanne). 2019;6:145.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3359_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1189\/jlb.0706426","volume":"81","author":"A Catania","year":"2007","unstructured":"Catania A. The melanocortin system in leukocyte biology. J Leukoc Biol. 2007;81(2):383\u201392.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"3359_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/brainsci7080104","volume":"7","author":"RP Lisak","year":"2017","unstructured":"Lisak RP, Benjamins JA. Melanocortins, melanocortin receptors and multiple sclerosis. Brain Sci. 2017;7(8):104.","journal-title":"Brain Sci"},{"key":"3359_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-3-030-44436-5_3","volume-title":"Tissue-specific cell signaling","author":"SS Pereira","year":"2020","unstructured":"Pereira SS, Lobato CB, Monteiro MP. Cell signaling within endocrine glands: thyroid, parathyroids and adrenal glands. In: Silva JV, Freitas MJ, Fardilha M, editors. Tissue-specific cell signaling. 1st ed. Switzerland: Springer; 2020. p. 63\u201390.","edition":"1"},{"key":"3359_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fendo.2019.00683","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang W, Guo DY, Lin YJ, Tao YX. Melanocortin regulation of inflammation. Front Endocrinol (Lausanne). 2019;10:683.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3359_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.56.1.1","volume":"56","author":"A Catania","year":"2004","unstructured":"Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1\u201329.","journal-title":"Pharmacol Rev"},{"key":"3359_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101206","volume":"48","author":"GSH Yeo","year":"2021","unstructured":"Yeo GSH, Chao DHM, Siegert AM, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206.","journal-title":"Mol Metab"},{"key":"3359_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fendo.2017.00013","volume":"8","author":"D Fridmanis","year":"2017","unstructured":"Fridmanis D, Roga A, Klovins J. ACTH receptor (MC2R) specificity: what do we know about underlying molecular mechanisms? Front Endocrinol (Lausanne). 2017;8:13.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3359_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s41030-022-00181-0","volume":"8","author":"M Mirsaeidi","year":"2022","unstructured":"Mirsaeidi M, Baughman RP. Repository corticotropin injection for the treatment of pulmonary sarcoidosis: a narrative review. Pulm Ther. 2022;8(1):43\u201355.","journal-title":"Pulm Ther"},{"key":"3359_CR48","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1100\/tsw.2010.173","volume":"10","author":"A Catania","year":"2010","unstructured":"Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. Sci World J. 2010;10:1840\u201353.","journal-title":"Sci World J"},{"issue":"7","key":"3359_CR49","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.4049\/jimmunol.175.7.4806","volume":"175","author":"A Cooper","year":"2005","unstructured":"Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol. 2005;175(7):4806\u201313.","journal-title":"J Immunol"},{"issue":"2","key":"3359_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.kint.2022.09.025","volume":"103","author":"X Guan","year":"2023","unstructured":"Guan X, Chen B, Malhotra DK, Gohara AF, Dworkin LD, Gong R. Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy. Kidney Int. 2023;103(2):331\u201342.","journal-title":"Kidney Int"},{"issue":"3","key":"3359_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1681\/ASN.2022050605","volume":"34","author":"B Chen","year":"2023","unstructured":"Chen B, Guan X, Gunning WT, et al. Negative modulation of B cell activation by melanocortin 1 receptor signaling protects against membranous nephropathy. J Am Soc Nephrol. 2023;34(3):467\u201381.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3359_CR52","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-022-00933-7","volume":"19","author":"F Xiao","year":"2022","unstructured":"Xiao F, Rui K, Shi X, et al. Epigenetic regulation of B cells and its role in autoimmune pathogenesis. Cell Mol Immunol. 2022;19(11):1215\u201334.","journal-title":"Cell Mol Immunol"},{"key":"3359_CR53","doi-asserted-by":"publisher","first-page":"1155421","DOI":"10.3389\/fimmu.2023.1155421","volume":"14","author":"S Iwata","year":"2023","unstructured":"Iwata S, Hajime Sumikawa M, Tanaka Y. B cell activation via immunometabolism in systemic lupus erythematosus. Front Immunol. 2023;14:1155421.","journal-title":"Front Immunol"},{"key":"3359_CR54","doi-asserted-by":"crossref","unstructured":"Wilbrink R, Spoorenberg A, Verstappen G, Kroese FGM. B cell involvement in the pathogenesis of ankylosing spondylitis. Int J Mol Sci. 2021; 22(24).","DOI":"10.3390\/ijms222413325"},{"key":"3359_CR55","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","volume":"9","author":"P Musette","year":"2018","unstructured":"Musette P, Bouaziz JD. B cell modulation strategies in autoimmune diseases: new concepts. Front Immunol. 2018;9:622.","journal-title":"Front Immunol"},{"key":"3359_CR56","first-page":"241","volume":"305","author":"RA Manz","year":"2006","unstructured":"Manz RA, Moser K, Burmester GR, Radbruch A, Hiepe F. Immunological memory stabilizing autoreactivity. Curr Top Microbiol Immunol. 2006;305:241\u201357.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"3359_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607\u201312.","journal-title":"Immunity"},{"key":"3359_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13075-015-0823-y","volume":"17","author":"NJ Olsen","year":"2015","unstructured":"Olsen NJ, Decker DA, Higgins P, et al. Direct effects of HP Acthar gel on human B lymphocyte activation in vitro. Arthritis Res Ther. 2015;17:300.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3359_CR59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cei.13089","volume":"192","author":"AL Benko","year":"2018","unstructured":"Benko AL, McAloose CA, Becker PM, et al. Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids. Clin Exp Immunol. 2018;192(1):68\u201381.","journal-title":"Clin Exp Immunol"},{"key":"3359_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clim.2019.02.009","volume":"201","author":"NJ Olsen","year":"2019","unstructured":"Olsen NJ, Benko AL, McAloose CA, et al. Repository corticotropin injection reverses critical elements of the TLR9\/B cell receptor activation response in human B cells in vitro. Clin Immunol. 2019;201:70\u20138.","journal-title":"Clin Immunol"},{"key":"3359_CR61","doi-asserted-by":"crossref","unstructured":"Decker DA, Grant C, Oh L, Becker PM, Young D, Jordan S. Immunomodulatory effects of H.P. Acthar gel on B cell development in the NZB\/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014; 23(8):802\u201312.","DOI":"10.1177\/0961203314531840"},{"issue":"4","key":"3359_CR62","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s40744-021-00351-7","volume":"8","author":"AD Askanase","year":"2021","unstructured":"Askanase AD, Wright D, Zhao E, Zhu J, Bilyk R, Furie RA. Post hoc biomarker analyses from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial of repository corticotropin injection (Acthar\u00ae Gel) for persistently active systemic lupus erythematosus. Rheumatol Ther. 2021;8(4):1871\u201386.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"3359_CR63","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.ekir.2021.06.010","volume":"6","author":"S Hartzell","year":"2021","unstructured":"Hartzell S, Sanchez-Russo L, Pecchio IP, et al. Repository corticotropin injections promote clinical remission and regulatory T cell expansion in membranous nephropathy. Kidney Int Rep. 2021;6(9):2491\u20135.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3359_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/08916934.2014.984836","volume":"48","author":"MF Cusick","year":"2015","unstructured":"Cusick MF, Libbey JE, Oh L, Jordan S, Fujinami RS. Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis. Autoimmunity. 2015;48(4):222\u201330.","journal-title":"Autoimmunity"},{"issue":"2","key":"3359_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jcph.582","volume":"56","author":"R Lal","year":"2016","unstructured":"Lal R, Bell S, Challenger R, et al. Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone. J Clin Pharmacol. 2016;56(2):195\u2013202.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3359_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/jir.2022.0257","volume":"43","author":"D Wright","year":"2023","unstructured":"Wright D, Hayes K. Acthar gel inhibits the activation of CD4(+) and CD8(+) T cells. J Interferon Cytokine Res. 2023;43(4):182\u20137.","journal-title":"J Interferon Cytokine Res"},{"key":"3359_CR67","unstructured":"Wright D, Fitch R. Repository corticotropin injection (RCI: HP Acthar gel) enhances remyelination after cuprizone-induced demyelination. Presented at: Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 28-June 1, 2019; Seattle, WA."},{"issue":"Suppl 2","key":"3359_CR68","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/annrheumdis-2019-eular.4127","volume":"78","author":"AD Wright","year":"2019","unstructured":"Wright AD, Zweifel B, Sharma P, Galen K, Fitch RM. Reduced steroidogenic activity of repository corticotropin injection (RCI) induces a distinct cytokine response following T cell activation in vivo. Ann Rheum Dis. 2019;78(Suppl 2):1504.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3359_CR69","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biopha.2011.11.009","volume":"66","author":"SA Brod","year":"2012","unstructured":"Brod SA, Bauer V, Hood Z. Oral ACTH (H.P. Acthar\u00ae gel) inhibits IL-1 and IL-17 secretion in humans. Biomed Pharmacother. 2012;66(1):36\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"3 suppl 1","key":"3359_CR70","first-page":"777","volume":"23","author":"LM Healy","year":"2017","unstructured":"Healy LM, Jang JH, Lin YH, Rao V, Antel JP, Wright D. Melanocortin receptor mediated anti-inflammatory effect of repository corticotropin injection on human monocyte derived macrophages [ECTRIMS-ACTRIMS abstract EP1481]. Mult Scler J. 2017;23(3 suppl 1):777.","journal-title":"Mult Scler J"},{"issue":"1","key":"3359_CR71","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1038\/s41598-020-64305-9","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chery S, Lazerson A, et al. Anti-inflammatory effects of alpha-MSH through p-CREB expression in sarcoidosis like granuloma model. Sci Rep. 2020;10(1):7277.","journal-title":"Sci Rep"},{"key":"3359_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577522","volume":"353","author":"AL Benko","year":"2021","unstructured":"Benko AL, Wright AD, Sunyer T, Olsen NJ, Kovacs WJ. Individual pituitary neuropeptides do not recapitulate the effects of repository corticotropin (Acthar\u00ae) on human B cells in vitro. J Neuroimmunol. 2021;353:577522.","journal-title":"J Neuroimmunol"},{"key":"3359_CR73","first-page":"A4264","volume":"203","author":"R Rovinski","year":"2021","unstructured":"Rovinski R, Tian R, Mirsaeidi M. Repository corticotropin injection has demonstrated anti-inflammatory effect in in vitro model of sarcoidosis granuloma. Am J Respir Crit Care Med. 2021;203:A4264.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3359_CR74","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12891-020-03609-3","volume":"21","author":"DA Decker","year":"2020","unstructured":"Decker DA, Higgins P, Hayes K, Bollinger C, Becker P, Wright D. Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept. BMC Musculoskelet Disord. 2020;21(1):586.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03359-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03359-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03359-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:46Z","timestamp":1762030966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03359-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3359"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03359-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mehdi Mirsaeidi does not have any conflicts of interest to disclose. Jeffrey Kaplan has served on and received compensation for speakers\u2019 bureaus from AbbVie, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Lundbeck, Mallinckrodt, TG Therapeutics, and Vanda. Dr. Kaplan is currently affiliated with AdventHealth Medical Group Neurology, Roeland Park, Kansas. John Affeldt has served on and received compensation for speakers' bureaus, advisory boards, and\/or consulting for Bausch & Lomb, Claris, Dompe, Kala, Mallinckrodt, ReGenTree, and Sun Pharmaceuticals. Regina Berkovich has received honoraria for speaking engagements, served on scientific advisory boards, and provided consulting for Alexion, Amgen, ANI Pharmaceuticals, Biogen, EMD Serono, Mallinckrodt Pharmaceuticals, Novartis, Sanofi, and TG Therapeutics. Anca Askanase has received consulting fees from AbbVie, Amgen, AstraZeneca, Aurinia, BMS, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals that were used in any of the experiments performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}